Clinical trials: Tyrosine Kinase Inhibitor
Acute Lung Injury
A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury
The study is a randomized, double-blind, placebo-controlled clinical study of imatinib (as mesilate) in healthy subjects exposed inhaled lipopolysaccharide.
- Trial name
- NCT03328117
- Testing
- Imatinib
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Exvastat Ltd.
Non-small Cell Lung Cancer
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
- Trial name
- ATPase (NCT05014464)
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors
The investigators propose a non-invasive prognostic tool for TKIs resistance in patients with stage IV EGFR-mutant non-small cell lung cancer (NSCLC) by computed tomography phenotypic features, which can be conveniently…
- Trial name
- NCT02851329
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Wet Age Related Macular Degeneration
Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops
To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers
- Trial name
- NCT06969001
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- SCAI Therapeutics
Chronic Myeloid Leukemia
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
- Trial name
- NCT07413263
- Testing
- Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Irritable Bowel Syndrome
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
This FTIH study is designed to assess the safety, tolerability and pharmacokinetic (PK) of escalating single and repeat oral doses of GSK3352589 in normal healthy volunteers.
- Trial name
- NCT03154086
- Testing
- GSK3352589
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.
- Trial name
- NCT05105607
- Testing
- D-4517.2
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor…
- Conditions
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer
- Trial name
- NCT06326502
- Testing
- ETN101
- Where
- 2 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Etnova Therapeutics Corp.
Chronic Lymphocytic Leukemia (CLL)
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.
- Trial name
- NCT07508995
- Testing
- BGB-16673, BGB-11417
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Healthy Volunteers
Comparison of HBW-3220 Capsule Formulations and the Effect of Food in Healthy Participants
This Phase 1 study will evaluate a new formulation of HBW-3220 capsules in healthy adults. It will compare how much and how quickly HBW-3220 enters the bloodstream after a single 120 mg dose of the new formulation versus the…
- Trial name
- NCT07799597
- Testing
- HBW-3220 Old Formulation Under Fasting Conditions, HBW-3220 New Formulation Under Fasting Conditions, HBW-3220 New Formulation Under Fed Conditions
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Myeloproliferative Neoplasm, Chronic Phase Chronic Myelogenous Leukemia
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
This trial looks at how well a distress reduction intervention, called "Being Present", works to improve the quality of life of patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs) or chronic phase chronic myeloid…
- Conditions
- Myeloproliferative Neoplasm, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT04605211
- Testing
- Online Mindfulness Meditation, Internet-Based Webinars
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Carcinoma, Adenoid Cystic
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
There is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma.
- Trial name
- NCT04974866
- Testing
- EGFR-TK Inhibitor
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Qingdao Central Hospital
Renal Cell Carcinoma, GIST
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
In this study the researchers investigate the influence of the tyrosine kinase inhibitors sunitinib and sorafenib, on the normal humoral and cellular immuno response to influenza vaccination in patients with metastases of renal…
- Trial name
- NCT00979381
- Testing
- influenza vaccine
- Where
- Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Bioavailability, B-cell Lymphoid Cancer
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
This study will be a 2-part, open-label, single-center relative bioavailability, PPI effect, food-effect and particle size effect randomized crossover study of acalabrutinib tablets in healthy subjects (males or females).
- Trial name
- NCT04488016
- Testing
- Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Treatment Free Remission, Chronic Myeloid Leukemia
Italian Treatment Free Remission Registry
The investigator propose an extension of the previous National, multicentric study, promoting an observational registry, both retrospective and prospective, in order to expand and further characterize the series of Italian…
- Trial name
- NCT04769947
- Where
- Italy
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Turin, Italy
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Tyrosine kinase inhibitors (TKI) have revolutionized the management and prognosis of chronic myeloid leukemia (CML). Daily treatment with TKI, which is necessary due to lack of cure, is frequently associated with moderate…
- Trial name
- NCT05753384
- Testing
- treatment of TKI in CML
- Where
- 20 sites in France
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Irritable Bowel Syndrome
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
GSK3179106 is a potent and relatively selective inhibitor of RET kinase which has been designed to be a safe and effective therapy for irritable bowel syndrome (IBS) patients .
- Trial name
- NCT02727283
- Testing
- GSK3179106
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Systemic Lupos Erythematosus, SLE
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
The primary objective of the study is to evaluate the safety and tolerability of single oral doses of BIIB068 in healthy participants.
- Trial name
- NCT02829541
- Testing
- BIIB068
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biogen
Solid Tumors Harboring NTRK Fusion
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
The researchers in this study want to gather information in healthy adult male participants about how the human body absorbs, distributes and excretes the drug selitrectinib including the effect of the interaction of food with…
- Trial name
- NCT04275960
- Testing
- Selitrectinib (BAY2731954)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer